Cancel
Bolt Biotherapeutics
See Linkedin
Bolt Biotherapeutics Employees
13 people indexed:
-
w8x723ka@hsz25g5.35a Sign up to see email
-
4y.0x5fk@uy1w6nh.dfu Sign up to see email
-
5xfwk18d4@kp0s11x.x87 Sign up to see email
-
kp45917@xxw3nv6.f4e Sign up to see email
-
ydq@23as748.r6p Sign up to see email
-
Michael N. Alonso
Vice President, Immunology & Pharmacology
4e.7796w7@zg6fr5v.uqr Sign up to see emailr7.d92w4k@365xv3x.7qp Sign up to see email -
7j7wx@rp5vquq.usx Sign up to see email
-
Pam Howland
Vice President, Portfolio and Program Management
x0z599gz@2k7j2rq.016 Sign up to see email38ksukyj@62se13u.71y Sign up to see email -
81qvgxy439@66y85xk.90y Sign up to see email
-
dk93a5@6r7044a.6k3 Sign up to see email
-
rqr@z1prgvw.jja Sign up to see email
-
6f367p5v@ky2s8an.0qv Sign up to see email
-
98pv5z@de6f9vd.4e8 Sign up to see email
Bolt Biotherapeutics' Founding and Background
Bolt Biotherapeutics was established in 2015 by Dr. Edgar G. Engleman, a renowned researcher from Stanford University. The company is headquartered in Redwood City, California. Dr. Engleman's vision was to create a biotech firm that develops innovative cancer therapies by leveraging both the innate and adaptive immune systems. His extensive background in immunology has been instrumental in guiding the company's research and development initiatives.
Bolt Biotherapeutics' Pipeline and Therapeutic Focus
Bolt Biotherapeutics focuses on developing tumor-targeted therapies. Their pipeline includes two major candidates: BDC-1001 and BDC-3042. BDC-1001 is currently in clinical development for HER2-positive cancers such as colorectal, endometrial, gastroesophageal, and metastatic breast cancer. BDC-3042 is being developed for cancers including triple-negative breast cancer and clear cell renal cell carcinoma. These candidates utilize the company's proprietary Boltbody™ ISAC platform to enhance the body's immune response against tumors.
Bolt Biotherapeutics' Boltbody™ ISAC Platform
The Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform is the cornerstone of Bolt Biotherapeutics' approach to cancer therapy. This proprietary technology is designed to harness and amplify the innate and adaptive immune responses to target and destroy cancer cells. By combining an antibody with an immune-stimulating agent, the Boltbody™ ISAC platform aims to create a more effective and sustained anti-tumor response, potentially leading to improved patient outcomes.
Bolt Biotherapeutics' Clinical Collaborations
Bolt Biotherapeutics actively engages in strategic collaborations to advance its clinical development programs. Notably, the company has partnered with pharmaceutical giants Bristol-Myers Squibb and Roche. These collaborations are focused on the clinical development and potential commercialization of Bolt's therapeutic candidates. Such partnerships not only provide valuable resources and expertise but also enhance the potential for successful clinical outcomes and broader market reach.
Bolt Biotherapeutics' Impact on Cancer Treatment
Bolt Biotherapeutics is making significant strides in the field of cancer treatment by developing innovative therapies that leverage the body's immune system. Their focus on HER2-positive and Dectin-2 related cancers addresses substantial unmet medical needs. By advancing candidates like BDC-1001 and BDC-3042 through clinical trials, Bolt Biotherapeutics aims to provide new, effective treatment options for patients with various types of cancer. Their pioneering work in immuno-oncology holds promise for transforming cancer care and improving patient survival rates.
Report inaccurate information
Report inaccurate information
